Learn More
Invitrogen™ Ocrelizumab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA541829
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes that express the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions which improves the benefit-to-risk profile for patients with relapsing or progressive forms of MS.
Specifications
| Ocrelizumab Humanized | |
| Recombinant Monoclonal | |
| Unconjugated | |
| Ocrevus | |
| Human MS4A1/CD20. | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid | |
| Chemical |
| ELISA, SDS-Page | |
| 5.1 mg/mL | |
| PBS with no preservative; pH 7.4 | |
| Human | |
| Protein A/G | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.